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Objective. To examine the role of adenosine receptor 2a gene (ADORA2a) polymorphisms on outcome of MTX treatment in RA.
Methods. Subjects included 309 RA patients with a defined response to MTX. Patients were included if they were (i) good responders
(n¼147) (ESR <20 for >6/12 on stable dose of MTX) (ii) inefficacy failures (n¼101) (physician statement and failure to reduce ESR/CRP by
20%) or (iii) adverse event (AE) failures (n¼61) (verified by medical record review). AEs were sub-divided into gastrointestinal (GI) (n¼24),
abnormal LFTs (n¼20) or other (n¼17). 8 single nucleotide polymorphisms (SNPs) within ADORA2a were genotyped using the Sequenom
MALDI-TOF platform.
Results. Five SNPs within ADORA2a were associated with stopping MTX for AEs (OR 2.1–3.07, P<0.05 for all). Analysis by AE type
showed that the association was specific for GI toxicity. No association was observed between ADORA2a and inefficacy outcomes.
Conclusion. Genetic variation within ADORA2a is significantly associated with AEs on MTX, specifically GI AEs. Knowledge of the
ADORA2a genotype may help to improve identification of patients at high risk of GI toxicity with MTX.
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Introduction
Methotrexate (MTX) is a cornerstone of therapy for RA.
However, its clinical efficacy is variable, with between 46% and
65% patients gaining a 20% improvement [1, 2]. MTX has anti-
proliferative effects, via effects on purine synthesis and folate
metabolism [3]. However, this is not its only mechanism of action
in RA, since co-administration of folic acid does not significantly
reduce efficacy although it does abrogate certain adverse
effects [4].
Studies suggest that its anti-inflammatory effects are mediated
via adenosine release, a potent anti-inflammatory nucleoside [5–7].
MTX polyglutamates inhibit the action of amino-imidazole-
carboxamidoadenosine-ribonucleotide transformylase (AICAR
transformylase) more potently than enzymes involved in purine
synthesis, causing an accumulation of AICAR and its metabolites.
These inhibit adenosine deaminase and adenosine monophosphate
(AMP) deaminase, leading to increased levels of endogenous
adenosine [3, 6]. Adenosine agonists have been shown to be
effective in murine models of arthritis [8]. Adenosine binds to
several receptor subtypes including A1, A2a, A2b and A3 [6].
Murine studies suggest a pivotal role for the A2a and A3 receptors
[8] with the administration of adenosine receptor antagonists,
caffeine and theophylline, being shown to effectively block the
effects of MTX [9]. Similarly, adenosine receptor 2a (ADORA2a)
agonists (e.g. CGS-21680) have anti-inflammatory actions similar
to MTX [10].
There is increasing interest in the potential of pharmacogenetics
to guide therapeutic decision making. Understanding MTX
pharmacogenetics may determine as to which patients are most
likely to respond to treatment and/or which patients may be more
susceptible to toxicity. Recent reports suggest that genetic
polymorphisms within the folate pathway may influence both
MTX toxicity [11] and efficacy [12, 13]. Within newly diagnosed
RA patients, Wessels et al. [14] demonstrated an association
between genes coding for adenosine release and good response
to MTX. In addition, they used a clinical pharmacogenetic model
to predict MTX efficacy in 205 newly diagnosed DMARD-naı¨ve
RA patients, with 60% of patients being classified as responders
or non-responders [15], although the utility of such a model in
patients with established disease has yet to be determined. Our
aim was to examine the association between MTX outcomes in a
well-characterized group of established RA patients and single
nucleotide polymorphisms (SNPs) within the adenosine receptor
2a (ADORA2a) gene.
Patients and methods
Study subjects and outcomes
Patients were retrospectively recruited from two hospital centres—
the University Hospital of North Staffordshire (UHNS) and
Central Manchester and Manchester Children’s University
Hospitals Trust (CMMC). UHNS has a computerized monitoring
database which records all drug histories, blood results and
clinical correspondence for each patient. Reasons for stopping
DMARDs are also entered into this database that records all
patients treated with MTX since 1986. At CMMC, case notes were
analysed prior to all RA follow-up clinics to identify patients
exposed to MTX monotherapy. Patients were considered eligible
for inclusion if they were aged over 18 yrs, of White Caucasian
ethnic origin, classified as having RA according to ARA criteria
[16] and had one of three defined outcomes to MTX (see
subsequently). Such patients were then approached to take part
in the study, although it should be noted that only one patient
considered eligible declined to take part.
(i) MTX responder: defined as patients who fulfilled three
criteria—physician statement of good response and ESR  20
and/or normal CRP with a stable dose of MTX for at least
6 months.
(ii) MTX inefficacy: defined as physician statement of inefficacy
plus failure to reduce ESR and/or CRP by at least 20% from
baseline. Patients had to have received a minimum dose of
15mg/week for at least 3 months.
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MTX it had to occur on treatment, resolve on treatment
cessation and in the case of gastrointestinal side-effects recur
on MTX rechallenge. AEs were further divided into subtypes:
(a) Gastrointestinal: nausea, vomiting or diarrhoea precluding
MTX continuation.
(b) Abnormal liver function: liver transaminases   twice the
upper limit of normal on at least two occasions, or biopsy
changes suggestive of toxicity.
(c) Other: haematological AEs, headaches, rashes or
pneumonitis.
None of the patients were taking oral steroids or other
DMARDs and all patients were taking at least 5mg folic acid
per week. Ethical approval for the study was obtained from North
Staffordshire and Central Manchester Local Research Ethics
Committees (Refs 03/20 and 03/CM/315, respectively) and all
patients provided written informed consent prior to taking part in
the study. Anonymized clinical data was abstracted from case
notes using a standard proforma by a single observer (S.L.H.).
Data collection and recruitment was completed using these pre-
defined outcomes prior to any genetic analysis taking place.
Genetic polymorphisms
SNPs within ADORA2a (Chr22q 11.2, two exons) were identified
using HapMap Phase I data and National Center for
Biotechnology Information. Eight validated SNPs with a reported
minor allele frequency (MAF) of >5% were selected (rs5760410,
rs2298383, rs3761422, rs2267076, rs4822489, rs2236624,
rs17650937, rs8192446). Genotyping was performed using
MassARRAY high-throughput DNA analysis with matrix-
assisted laser desorption ionization time-of-flight (MALDI-
TOF) mass spectrometry (Sequenom, San Diego, CA, USA,
www.sequenom.com).
Statistical analysis
Quality control. Hardy–Weinberg equilibrium (HWE) was
determined using STATA v8 software (Stata Corp). SNPs were
removed from analysis using pre-defined quality control (QC)
standards (i) if deviation from HWE (P 0.05) was observed in
the responders (used as controls), (ii) if the genotyping success rate
was <85% or (iii) if the MAF within our cohort was <5%.
Single-point analysis. Genotype frequencies were compared
between the three groups using a chi-squared test, then analysed
as a nested case–control study using the responders as the referent
category. For significant results (P<0.05) 2 2 contingency
tables were used to generate odds ratios (ORs with 95%CIs),
based on carriage of the rare allele. For SNPs showing a
significant genotypic association (P<0.05), permutation testing
was performed to limit type II error. Empirical P-values were
generated using PLINK, a Monte Carlo-based method for
assessing significance of case–control association studies
(http://pngu.mgh.harvard.edu/ purcell/plink/). Ten thousand
simulations were performed. PLINK generates both uncorrected
(EMP1) and corrected (EMP2) empirical P-values. The corrected
empirical P-value (EMP2) calculates the proportion of permuta-
tions in which any of the test statistics exceeded that particular
observed statistic. It does not assume that the tests are
independent, but it still controls the probability of observing at
least one false positive per experiment and hence is more stringent
than the conventional EMP1P-value. In both cases, P-values of
<0.05 were taken as significant.
Results
We studied 309 RA patients (for clinical data, see
supplementary table 1, available as supplementary data at
Rheumatology Online), including 147 good responders, 101
inefficacy failures and 61 AE failures. The AEs included
gastrointestinal (n¼24), abnormal liver function tests (n¼20)
and other (n¼17, including haematological (n¼7) and skin
rashes (n¼6).
Of the eight SNPs tested within ADORA2a, three failed
QC (rs4822489 [genotyping success <85%, rs8192446 (non-
polymorphic) and rs17650937 (MAF <5%)] leaving five SNPs
for further analysis. These SNPs provided 100% pairwise cover-
age of the ADORA2a gene based on HapMap Phase I data (for
linkage disequilibrium data, see supplementary table 2, available
as supplementary data at Rheumatology Online). There was a
significant difference across the three outcome groups for SNPs
rs3761422 and rs2236624 (Table 1). All five SNPs were
significantly associated with AEs (Table 1). Even applying the
more stringent corrected permutation P-values (EMP2 in
Table 1); two of the SNPs remained significantly associated with
AEs. The AE group was then stratified by type and a consistent
association was observed between gastrointestinal (GI) AEs and
all five SNPs (Table 1). After corrected permutation P-values were
applied, one SNP (rs3761422) remained significant and two other
SNPs were borderline (rs5760410 and rs2298383, P¼0.06 for
each). Table 2 illustrates the odds of having any AE (or GI AE)
compared with responders with carriage of the variant allele.
TABLE 1. Genotype frequencies for ADORA2a SNPs
Responders vs AEs Responders vs GI AEs
Genotype (% success)
R
n (%)
IE
n (%)
AE
n (%) Global chi
R vs IE
PP EMP1 EMP2
Genotype
GI AE n (%) P EMP1 EMP2
rs 5760410 (85.1) AA 38 (31) 26 (30) 7 (13) 0.09 0.75 0.033 0.03 0.1 2 (9) 0.03 0.02 0.06
AG 63 (52) 43 (49) 37 (69) 12 (56)
GG 20 (17) 18 (21) 10 (19) 8 (36)
rs 2298383 (92.6) CC 53 (38) 37 (40) 12 (22) 0.12 0.87 0.04 0.04 0.1 4 (19) 0.03 0.02 0.06
CT 71 (52) 45 (48) 32 (58) 11 (52)
TT 14 (10) 11 (12) 11 (20) 6 (29)
rs 3761422 (94.8) CC 62 (44) 39 (42) 16 (27) 0.05 0.87 0.012 0.01 0.03 7 (29) 0.001 0.002 0.004
CT 68 (48) 45 (48) 31 (53) 9 (38)
TT 11 (8) 9 (10) 12 (20) 8 (33)
rs 2267076 (95.4) CC 68 (49) 44 (45) 18 (31) 0.12 0.88 0.036 0.03 0.1 8 (35) 0.05 0.04 0.1
CT 59 (42) 44 (45) 29 (50) 9 (39)
TT 13 (10) 9 (9) 11 (19) 6 (26)
rs 2236624 (95.1) CC 86 (62) 57 (59) 22 (37) 0.02 0.39 0.004 0.004 0.01 9 (38) 0.05 0.03 0.1
CT 44 (32) 36 (38) 33 (56) 11 (46)
TT 9 (6) 3 (3) 4 (7) 4 (17)
The table illustrates the genotype frequencies for the ADORA2a SNPs together with chi-squared results among the three groups, and responders (R) vs inefficacy (IE) and then AEs. All data
is presented as n (%). The results of the permutation testing are displayed as with uncorrected P-values (EMP1) and with the permuted P-values corrected for the number of tests performed (EMP2).
Data is then presented for GI AEs compared with responders, again with uncorrected P-value, and then EMP1 and EMP2.
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all five loci (OR 2.1–3.07, P<0.05 for all). In subgroup analysis,
carriage of the variant allele was significantly associated with GI
AEs at two of the five loci. Although the numbers are small,
homozygosity of the variant allele was associated with GI AEs at
four loci (OR 2.9–5.9, P<0.05).
Discussion
A key anti-inflammatory mechanism of MTX is via the release of
adenosine acting at several receptors. Our analysis demonstrates
an association between five SNPs in the ADORA2a gene and AEs
(specifically GI) on MTX. No association was observed between
ADORA2a polymorphisms and MTX inefficacy. While this is the
first study of ADORA2a receptor polymorphisms in RA, others
have shown associations between ATIC polymorphisms and AEs
on MTX [14], specifically GI AEs [11] supporting the concept that
the adenosine pathway is important in determining AEs on MTX.
There are several possible mechanisms for MTX-induced GI
AEs such as nausea. First, it may be due to local anti-proliferative
effects on gut tissue, although the risk of this is reduced by
co-prescription of folic acid, which all of our patients received.
Alternatively, MTX-induced nausea may be due to sensitization
of central chemoreceptors. MTX-associated nausea may be
treated using 5HT3 antagonists, such as ondansetron and
granisetron, which act via central nervous system (CNS) receptors
around the basal ganglion [17, 18]. It is of interest that the
ADORA2a receptor is strongly expressed within the CNS,
especially around the basal ganglia [19]. Our study raises the
hypothesis that central sensitization to MTX limits its tolerability
and that variation in the ADORA2a receptor may mediate this.
Further studies are now needed, both to replicate our findings and
to examine the mechanisms behind this observation. ADORA2a
polymorphisms have previously been associated with panic
disorder [20] and anxiety response to amphetamine [21] again
suggesting important central effects of this receptor.
There are several strengths and weaknesses of the study which
need to be considered when interpreting the results. With regard
to study design, patients were identified retrospectively and our
phenotypes were pre-defined using data that was available on all
patients (thus ESR and CRP were used as surrogates for defining
response rather than formal joint counts that were not available
for all patients). Clearly drug response is a spectrum, and in a
prospective design, a composite measure of response such as the
disease activity score 28 (DAS28) would be preferable. However,
our patient populations were selected on the basis of pre-defined,
well-characterized phenotypes in an attempt to minimize variation
in the clinical phenotype and improve our ability to detect
important genetic effects.
Establishing causality of AEs is difficult, and therefore we
chose to recruit only patients with AEs severe enough to require
treatment cessation so that those recorded were likely to be
correctly attributable to the MTX. We recognize that other factors
(both clinical and psychosocial) may influence both the likelihood
of and reporting of AEs. As the majority of patients were
monitored in hospital we feel that significant AE unreporting is
unlikely. Further studies are, however, needed to determine the
positive predictive value of these polymorphisms and determine
whether there is any association with patients who experience but
tolerate milder AEs.
A key limitation of our study is the small numbers in each
group. However, this cohort is one of the largest studied to date in
the context of RA MTX pharmacogenetics. Importantly, the
observed associations remained significant after permutation
testing, suggesting that the findings are robust and not simply
due to Type II error. Nevertheless, given the size of the cohort we
felt that further haplotype analysis was not appropriate. However,
given that the SNPs are in relatively strong linkage disequilibrium
it is difficult to separate the effects and determine which is the
functionally relevant SNP. To date the functional effects of these
SNPs are not known. Further work is therefore required both to
replicate these findings and determine the functional effect of
these polymorphisms.
In summary, we report a novel association between ADORA2a
polymorphisms and AEs in MTX-treated RA patients.
Specifically, associations were observed between several
ADORA2a SNPs and GI AEs on MTX. These results support
the work of others suggesting that the outcome of MTX therapy is
in part, genetically determined. Further studies are required to
confirm and refine these observations and examine the pragmatic
value of pharmacogenetic testing in RA patients commencing
therapy with MTX.
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